Related Experiment Video
Updated: May 5, 2026
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Early Use of Aspirin for Coronary Allograft Prophylaxis in Heart Transplant Recipients
Cassia Kessler Iglesias1,2, Jason E Bloom3,4, Xiaoman Xiao3
1Heart Failure and Transplant Unit, Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia.
Insights
Early aspirin use after heart transplantation may reduce mortality and potentially prevent coronary allograft vasculopathy (CAV). Further research is needed to confirm these findings in larger trials.
Area of Science:
- Cardiology
- Transplantation Immunology
Background:
- Coronary allograft vasculopathy (CAV) is a major complication after heart transplantation.
- Aspirin is being investigated as a potential prophylactic agent for CAV.
Purpose of the Study:
- To evaluate the association between early aspirin administration and the development of CAV and mortality in heart transplant recipients.
Main Methods:
- A retrospective cohort study of 372 heart transplant patients (January 2009-March 2018).
- Patients were stratified based on aspirin initiation during the index transplant admission.
- Primary outcome: moderate to severe CAV (ISHLT grade ≥2); Secondary outcome: mortality.
Main Results:
- Early aspirin use was associated with significantly reduced mortality (aHR=0.19).
- A trend towards a protective effect against moderate or severe CAV was observed (aHR=0.24).
- No differences in baseline characteristics were noted between groups.
Conclusions:
- Early aspirin administration in heart transplant recipients is linked to lower mortality and a potential reduction in CAV development.
- These findings require confirmation through prospective randomized controlled trials.
Background:
Coronary allograft vasculopathy (CAV) remains a significant cause of morbidity and mortality after heart transplantation. The use of aspirin for CAV prophylaxis has recently garnered interest as a possible therapeutic adjunct in this setting.
Methods:
This 2-center retrospective cohort study included 372 patients who underwent heart transplantation between January 2009 and March 2018 and were stratified according to the commencement of aspirin during their index transplant admission. The primary outcome was the development of moderate or severe CAV (International Society for Heart and Lung Transplantation grade ≥2) at surveillance coronary angiography. Secondary endpoints included mortality at follow-up.
Results:
There were no differences in age, sex, and cause of heart failure. In the early aspirin group, the preponderant risk factors included use of ventricular assist devices, pretransplant smoking, and mild or moderate rejection. Multivariable analyses to assess for independent predictors of CAV development and mortality demonstrated that aspirin was associated with reduced mortality (adjusted hazard ratio = 0.19; 95% confidence interval, 0.08-0.47, P < 0.01) and a trend toward a protective effect against the development of moderate or severe CAV (adjusted hazard ratio = 0.24; 95% confidence interval, 0.54-1.19; P = 0.08).
Conclusions:
In this retrospective risk-adjusted 2-center cohort study, early aspirin administration was associated with reduced risk of death and a trend toward a protective effect against CAV development. These findings warrant validation in prospective randomized trials.
More Related Videos
08:30A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
12:40A Modified Murine Heterotopic Heart Transplant Protocol Matching Contemporary Standards of Aseptic Technique, Anesthesia, and Analgesia
Published on: September 28, 2022
